Sectors

Mission Bay Capital, the venture capital arm of California Institute for Quantitative Biosciences, helped the replacement therapy developer close its series B round.

Long-term investor Boston Scientific is paying $295m upfront for the 73% of the ablation technology developer it does not own.

LinkedIn's data streaming spinoff, Confluent, is floating above its range in an offering effectively doubling the valuation of its last funding round to over $9bn.

The Tencent-backed social media app developer was aiming to raise $198m in the offering but has withdrawn in favour of alternative financing options.

PayPal and Visa have backed Blockchain Capital’s fifth flagship fund, which received $300m of commitments and which will focus on blockchain technology and cryptocurrencies.

Internet and telecommunications group SoftBank took part in the round, which will fund the business finance provider's acquisition strategy.

Deutsche Telekom Capital Partners invested in a series D round for the call centre technology provider led by Goldman Sachs Asset Management.

Sanofi Ventures co-led replacement therapy developer Glycomine's latest round, which included Novo, Asahi Kasei Pharma Ventures and Chiesi Ventures.

Alexandria Venture Investments backed precision immunology therapeutics developer ImmuneID in the round, which was led by venture capital firm Alta Partners.

Shell, Taavura Group and Menora Mivtachim-backed Nostromo secured $13.6m through a reverse merger with publicly-listed Somoto.

Boston Scientific has acquired all remaining shares in its portfolio company Farapulse, having first invested in the University of Iowa spinout in 2014.